

NIH GUIDE

for GRANTS and CONTRACTS

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Vol. 11, Nov. 13, December 13, 1982

IN THIS ISSUE:

Errata

Biomedical Research Support Shared
Instrumentation Grants Page 1
Division of Research Resources
Index - DRR

Fundamental Neurosciences: Neurophysiology
of Cognitive Processes Page 1
National Institute of Neurological and
Communicative Disorders and Stroke
Index - NINCDS

Notice

Clinical Cancer Education Page 1
National Cancer Institute
Index - NCI

Notice

Revised PHS Grants Policy Statement
now Available Page 2
Index - PHS Grants Policy Statement

Reminder Notice

Deadline for Submission of Assurances of
Compliance with Revised Human Subjects
Protection Regulations Page 3
Index - Human Subjects

(Continued)

HAVE YOU MOVED?

If your present address differs from that shown on the address label, please send your new address to: Grants and Contract Guide Distribution Center, National Institutes of Health, Room B3BN10, Building 31, Bethesda, Maryland 20205, and attach your address label to your letter. Prompt notice of your change of address will prevent your name from being removed from our mailing list.

The GUIDE is published at irregular intervals to announce scientific initiatives and to provide policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in grants and contracts activities administered by the National Institutes of Health.

Two types of supplements are published by the respective awarding units. Those printed on yellow paper concern contracts: solicitations of sources and announcement of availability of requests for proposals. Those printed on blue paper concern invitations for grant applications in well-defined scientific areas to accomplish specific program purposes.

Page 2 - Index (Continued)

Notice

Cell Culture Identification Service Page 4
National Cancer Institute
Index - NCI

Notice

Teaching Nursing Home (TNH) Award Page 5
National Institute on Aging
Index - NIA

Announcement

Participants Sought for National
Cooperative Drug Discovery Groups Page 6
Division of Cancer Treatment
National Cancer Institute
Index - Cancer

Notice

Request for Applications (RFA) Available
Side Effect Assessment in Psychopharmacologic
Clinical Trials Page 8
PHS, ADAMHA
National Institute of Mental Health
Index - Clinical Trials

Announcement

Small Grants for Occupational Safety and
Health Research Page 9
PHS, Centers for Disease Control
National Institute for Occupational
Safety and Health
Index - Occupational Safety and Health

Announcement

Availability of Requests for Applications
Coronary Artery Reactivity, Injury
and Thrombosis Page 13
Dysrhythmias in the Developing and
Immature Heart..... Page 13
Biobehavioral Factors Affecting
Hypertension in Blacks..... Page 14
Cardiac Hypertrophy and Failure in
Chronic Hypertension..... Page 15
Division of Heart and Vascular Diseases
National Heart, Lung, and Blood Institute
Index - Heart, Lung, and Blood

Announcement

Preventive Cardiology Academic Award..... Page 16
National Heart, Lung, and Blood Institute
Index - Heart, Lung, and Blood

Page 3 Index (Continued)

Announcement

Immunohistochemical Classification
of Solid Tumors Page 20
National Cancer Institute
Index - Cancer

Announcement

Development of Myeloma or Human B Cell
Lines Suitable for Somatic Cell
Hybridization to Produce Human
Monoclonal Antibodies Page 22
National Cancer Institute
Index - Cancer

Announcement

Research Grants on Hormones and Epilepsy Page 24
National Institute of Neurological
and Communicative Disorders and Stroke
Index - Neurological and Communicative Disorders
and Stroke

ERRATA

BIOMEDICAL RESEARCH SUPPORT SHARED INSTRUMENTATION GRANTS

An Announcement in the November 5, 1982, NIH Guide for Grants and Contracts (Vol. 11, No. 12) entitled "Biomedical Research Support Shared Instrumentation Grants," Division of Research Resources, has the following errors:

1. Page 1 - Application Receipt Date should be: February 15, 1983.
2. Page 8 - The telephone number was omitted from the address of the Biomedical Research Support Grant Program. The telephone number should be: (301) 496-6743.
3. Page 8 - The last two-line paragraph on the page should be omitted.

FUNDAMENTAL NEUROSCIENCES: NEUROPHYSIOLOGY OF COGNITIVE PROCESSES

An Announcement in the November 5, 1982, NIH Guide for Grants and Contracts (Vol. 11, No. 12) printed on page 23, from the Fundamental Neurosciences Program, National Institute of Neurological and Communicative Disorders and Stroke, failed to include the title for this program. The title should be "RESEARCH GRANTS IN THE NEUROPHYSIOLOGY OF COGNITIVE PROCESSES."

NOTICE

CLINICAL CANCER EDUCATION

NATIONAL CANCER INSTITUTE

The Clinical Cancer Education Program announces that until new guidelines for the program are written and approved, no new and competing renewal applications will be accepted. At that time, the new guidelines together with information on the receipt dates for applications will be published.

NOTICE

REVISED PHS GRANTS POLICY STATEMENT NOW AVAILABLE

The revision of the Public Health Service Grants Policy Statement is now available. The successor to the October 1, 1976 issuance is designated as DHHS Publication No. (OASH) 82-50,000 (Rev.) December 1, 1982. The Public Health Service has sent one free copy to each grantee institution of record addressed to: "Director, Office of Research Program Support." NIH hopes to make some limited additional distribution; however, institutions or individuals desiring additional copies may obtain them for \$5.00 each by writing to:

Superintendent of Documents
U.S. Government Printing Office
Washington, D.C. 20402

In addition to the DHHS Publication Number referenced above, requests should include the GPO Stock No. 017-020-00090-01 to expedite delivery.

Questions of interpretation, clarification, or correction will be provided as necessary in subsequent issuances of this Guide or other official communications.

REMINDER NOTICE

**DEADLINE FOR SUBMISSION OF ASSURANCES OF COMPLIANCE WITH
REVISED HUMAN SUBJECTS PROTECTION REGULATIONS**

On January 26, 1981, the Department of Health and Human Services (DHHS) published final regulations amending basic DHHS policy for the protection of human research subjects. Institutions holding an Assurance of Compliance were encouraged to implement new provisions of the regulations prior to the negotiation of a revised Assurance of Compliance. Since August, 1981, the Office for Protection from Research Risks (OPRR) has been negotiating Assurances of Compliance with the new regulations.

This notification is to remind institutions of the December 31, 1982 deadline, for submission of a general (Multiple Project) assurance prepared in accord with DHHS regulations published in the Federal Register on January 16, 1981 (46 FR 8366).

Institutions are encouraged to submit an Assurance of Compliance at the earliest possible date. A sample assurance is available from OPRR (301 - 496-7041). Although it is possible that approval of a multiple project assurance might not be transmitted until sometime after December 31, 1982, institutions may continue to function under their former assurance until such time as approval for the revised assurance is given. Special (Single Project) assurances will continue to be approved on a single project basis. GENERAL ASSURANCES WHICH HAVE NOT BEEN REVISED TO MEET THE 1981 REQUIREMENTS AND SUBMITTED TO OPRR WILL BE TERMINATED EFFECTIVE JANUARY 1, 1983.

NOTICE

CELL CULTURE IDENTIFICATION SERVICE

NATIONAL CANCER INSTITUTE

This announcement is being issued to inform investigators of the availability of a service for the inter- and intra-species identification of cell cultures.

The Biological Carcinogenesis Branch (BCB), Carcinogenesis Extramural Program, National Cancer Institute (NCI), has a continuing interest in the proper characterization of established cell lines. Therefore, the BCB has supported under contract N01-CP-21017 with the Children's Hospital of Michigan a service facility to aid in confirming or establishing species and intraspecies identity of cell cultures. This service, available to all interested investigators, uses species specific immunofluorescence, isoenzyme analysis, and cytogenetic examination.

Evaluation of cell cultures with species-specific antisera can rapidly identify the species of the cell line and determine whether more than one cell species is present. Isozyme analysis confirms species determination. Multiple polymorphic isozymes are helpful in precisely identifying human cell lines. Chromosomal analysis, using banding techniques, denotes chromosome numbers and markers that uniquely distinguish among cell lines. These examinations also contribute to information about changes in cultures that may have resulted from experimental manipulation. During the past several years, this cell monitoring service has proven useful to many investigators because it has provided critical information to them about the current status of their cell lines. It has also been useful in detecting cell contamination problems.

A modest service fee is charged that covers partial costs for the work done. The fee schedule is available upon request.

Investigators interested in making use of this service should contact:

Dr. Ward D. Peterson, Jr.
Child Research Center
Children's Hospital of Michigan
3901 Beaubien Boulevard
Detroit, Michigan 48201

Telephone: (313) 494-5570

NOTICE

TEACHING NURSING HOME (TNH) AWARD

NATIONAL INSTITUTE ON AGING

Prospective applicants for the National Institute on Aging (NIA) Teaching Nursing Home (TNH) award are advised that the TNH award has been changed to a Program Project (P01) support mechanism. This change requires that applications for the TNH program project award be limited to a total of \$500,000 for direct costs, including core support not to exceed \$125,000.

Supplementary information is available on preparation of applications for the TNH under program project guidelines. Requests for information on TNH applications may be obtained from:

Noel D. List, M.D., M.P.H.
National Institute on Aging
National Institutes of Health
Building 31 - Room 5C-21
Bethesda, Maryland 20205

Telephone: (301) 496-6761

ANNOUNCEMENT

PARTICIPANTS SOUGHT FOR NATIONAL COOPERATIVE

DRUG DISCOVERY GROUPS

DIVISION OF CANCER TREATMENT

NATIONAL CANCER INSTITUTE

Chemotherapy has had a major impact on the cure of cancer over the past two decades. Nevertheless, there is considerable need for the discovery of new and more efficacious agents with higher therapeutic ratios for the treatment of these diseases. Many exciting leads in fundamental science are available for possible exploration and possible extrapolation into new drug classes with unique mechanisms of action, and new approaches to control cancer. Considerable research talent is available nationally that could be employed in a very effective manner. However, to accomplish this requires a national support mechanism that would permit the most outstanding investigators in chemistry, biology, biochemistry and pharmacology (all needed for effective drug discovery) to interact in a manner that leads to the efficient invention of new strategies and entities for the treatment of cancer. Since it is clear that few single institutions possess a critical mass of all of the varied talents needed for effective drug discovery, a new instrument that permits the combination of the available expertise from diverse institutions is required. These units, termed National Cooperative Drug Discovery Groups (NCDDG) are envisioned to have the capacity to generate new approaches to therapeutic inventions, to rapidly translate their concepts into new chemical entities, to conduct adequate and unique biological evaluations, and to carry out in-depth biochemical and pharmacological studies. It is expected that the NCDDG, because of their unique ability to apply highly sophisticated multi-disciplinary technologies in concert, will discover and bring new entities to a pre-clinical stage that will allow the most enlightened use of other DCT resources for rapid development and clinical evaluation.

The Developmental Therapeutics Program (DTP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI) is proposing to establish the NCDDG. The goal of the NCDDG will be the discovery of new, clinically effective anticancer agents. While the compounds investigated may have synthetic, natural product or semi-synthetic origins, all proposed projects must have a strong scientific rationale. As currently envisioned, the basic scientific composition of a NCDDG would consist of programs in at least four scientific disciplines: chemistry, biology, biochemistry and pharmacology. The Groups would be organized under a Group Director (Principal Investigator) who will assemble a multi-institutional group of Program Leaders. This Group would contain the diversity of outstanding scientific skills needed to conduct a vigorous and effective new drug discovery effort. Emphasis will be on new structural types rather than analogs of known active compounds. The ultimate accomplishments of a NCDDG will, in large measure, depend on the skill of the Group Director in identifying likely targets for this effort and in blending the work of multiple scientific leaders toward a common goal. After formation of a NCDDG, it is intended that DTP will interact closely with the Groups. DTP will be responsible for the development (formulation, toxicology) of successful drug candidates to clinical trial.

The purpose of this initial announcement is to allow outstanding scientists who are interested in participating as a Group Director (i.e., Principal Investigator responsible for group formation, proposal preparation, and overall administration of the Group) or Program Leader (chemistry, biology, etc., see above) to identify themselves. It is the intention of DTP to tabulate and distribute this information within 30 days of announcement closing to all who respond to this announcement. This should help compatible scientists form strong, multi-institutional groups for the submission of applications which address this approach to anticancer drug discovery. Proposals that include more than 50% of the effort from a single campus or organization are discouraged. This announcement is intended only to expedite the formation of the groups. The DCT plans to issue a Request for Application (RFA) outlining the specifics of the NCDDG Program. Such an RFA will not be restricted to respondents to this announcement. The NCI will play no role in the formation of the Groups other than to distribute the information described above. The final composition of applicant groups may include respondents to this announcement or other scientists expressing interest at a later date.

Leading scientists from academia, research institutions and industry who are interested in leading or participating in a NCDDG should submit ONLY the following information which will be tabulated and sent to investigators supplying information:

Name
Institution (including Department, mailing address
and telephone number)
Scientific discipline (Chemistry, Biology,
Biochemistry, Pharmacology, Other)
Participation level interest (Group Director
and/or Program Leader)

This information should be sent by January 17, 1983 to:

Dr. John M. Venditti
Chief, Drug Evaluation Branch
Developmental Therapeutics Program
Division of Cancer Treatment
National Cancer Institute
National Institutes of Health
Blair Building - Room 428
8300 Colesville Road
Silver Spring, Maryland 20910

Telephone: (301) 427-8703

NOTICE

REQUEST FOR APPLICATIONS (RFA) AVAILABLE

SIDE EFFECT ASSESSMENT IN PSYCHOPHARMACOLOGIC CLINICAL TRIALS

**PUBLIC HEALTH SERVICE
ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION
NATIONAL INSTITUTE OF MENTAL HEALTH**

Application Receipt Date: March 1, 1983

As part of its mission to stimulate and support treatment assessment research for pharmacologic and somatic therapies of mental disorders, the Pharmacologic and Somatic Treatments Research Branch (PSTRB), National Institute of Mental Health (NIMH) has sought to improve the methodology and techniques available to assess these therapies. Assessment of adverse consequences (side effects) in clinical trials of psychotropic drugs has lagged significantly behind measurement of the intended therapeutic effects (efficacy) of these agents. In recognition of these problems, PSTRB, NIMH, initiated a program to develop methodology for the assessment of adverse consequences of psychotropic drugs in the context of clinical trials.

A technique for rating adverse drug reactions, Systematic Assessment for Treatment Emergent Events (SAFTEE), has been developed and tested for feasibility in clinical trial settings. The rating system includes both elicitation procedures and a recording form on which to report the information elicited about the events at each examination. There are two distinct levels of elicitation, "General Inquiry" and "Systematic Inquiry," each with specific examination procedures.

The purpose of this Request for Applications (RFA) is to invite applications to investigate systematically the reliability, validity, and characteristics of the new methodology when used in clinical trials under a range of conditions, specifically when used with various patients populations, different pharmacologic agents, raters representing different disciplines, and varying options for assessment called for by study protocols.

Copies of the complete Request for Applications, SAFTEE and additional information may be obtained from Jerome Levine, M.D., Chief, or Nina R. Schooler, Ph.D., Assistant Chief, at the following address:

Pharmacologic and Somatic Treatments
Research Branch
National Institute of Mental Health
Parklawn Building - Room 10C-06
5600 Fishers Lane
Rockville, Maryland 20857

Telephone: (301) 443-3524

Applications for this specific funding initiative should be submitted by the March 1, 1983 receipt date.

ANNOUNCEMENT

SMALL GRANTS FOR OCCUPATIONAL SAFETY AND HEALTH RESEARCH

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
CENTERS FOR DISEASE CONTROL
NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH**

The National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control (CDC), announces that competitive grant applications for small grants to support occupational safety and health research will be accepted until January 3, 1983.

I. PURPOSE

This NIOSH Small Grant Program invites applications for research grants covering scientific areas relevant to occupational safety and health and is intended to provide financial support for investigators who do not have Federal or non-Federal research grant support. The grants may be used to carry out exploratory or pilot studies, to develop or test new techniques or methods, or to analyze data previously collected. Examples of programmatic areas of interest are traumatic injuries, reproductive effects, neurologic and cardiovascular effects, occupational respiratory diseases, occupational cancers, musculoskeletal injuries, noise-induced hearing loss, dermatologic problems, and psychologic disorders. Potential applicants with questions concerning the acceptability of their proposed work should contact the individuals listed in this announcement.

II. AUTHORITY

These grants will be awarded and administered by NIOSH under the research and demonstration grant authority of section 20(a)(1) of the Occupational Safety and Health Act of 1970 (29 U.S.C. 669(a)(1)) and section 501 of the Federal Mine Safety and Health Act of 1977 (30 U.S.C. 951). Program regulations applicable to these grants are contained in Part 87 of Title 42, Code of Federal Regulations, "National Institute for Occupational Safety and Health Research and Demonstration Grants." Except as otherwise indicated, the basic grant administration policies of the Public Health Service are applicable to this program. Applications responsive to this announcement are not subject to OMB Circular A-95 Clearinghouse and/or Health Systems Agency review. This program is described in the Catalog of Federal Domestic Assistance No. 13.262, Occupation Safety and Health Research Grants.

III. ELIGIBLE APPLICANTS

This program is intended primarily for predoctoral graduate students and postdoctoral researchers; however, investigators from any scientific discipline and at any stage of their careers may apply for these grants.

Support under this program may not be requested to supplement research projects receiving Federal or non-Federal support or to provide interim support of projects under review by the Public Health Service. A grant application responsive to this announcement, submitted simultaneously with a regular research grant application on the same topic, will not be accepted.

IV. AVAILABILITY OF FUNDS

The total grant award may comprise direct costs of up to \$15,000 per year and additional indirect costs, as appropriate. The grants may be awarded for up to two years and will not be renewable. It is anticipated that the total annual amount available for grants under this program will be \$300,000. The specific amount to be funded will, however, depend upon the merit and scope of the applications received and the availability of funds. Grantees will be required to cost share a minimum of 5 percent.

V. ALLOWABLE EXPENSES (direct costs)

Support may be requested for the following categories:

1. Supplies.
2. Travel to attend a domestic meeting or visit another laboratory for the purpose of gathering more information or to learn a new technique or procedure relevant to the application. Relevance and importance must be justified in the applications.
3. Small items of equipment. The purchase of large equipment is discouraged.
4. Salary for technical personnel. Salary of the principal investigator will be allowed only with strong justification.

VI. CRITERIA FOR REVIEW

Applications will be reviewed by an appropriate scientific review group on the basis of scientific merit and significance of the project, scientific competence of the proposed principal investigator and supporting faculty (where appropriate) in relation to the type of research involved, feasibility of the project, likelihood of its producing meaningful results, appropriateness of the proposed budget, adequacy of the applicant's resources available for the project, and the supportive nature of the research environment. For those applications from students, the review process will take into consideration the fact that the applicants do not have extensive experience with the grant process.

VII. APPLICATION AND AWARD

Applications should be submitted on form PHS 398 (Rev. 5/80), available at most institutional business offices. Application kits may also be obtained from:

Office of Grants Inquiries
Division of Research Grants
National Institutes of Health
Westwood Building - Room 448
5333 Westbard Avenue
Bethesda, Maryland 20205

Telephone: (301) 496-7441

Care should be taken in following the instructions included with the application form, making certain to address the points identified under the heading "REVIEW CRITERIA."

An original and six copies of the application must be received no later than January 3, 1983, in order to be considered in the February/March 1983 Study Section meeting. Completed applications must be sent or delivered to:

Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building - Room 240
5333 Westbard Avenue
Bethesda, Maryland 20205

A brief covering letter should accompany the application indicating that it is submitted in response to this announcement.

Applicants may meet the deadline by either delivering or mailing the application on or before the above specified date provided the following conditions are met:

- A. Mailed applications. Applications mailed through the U.S. Postal Service will be considered as meeting the deadline if they are either:
 1. Received on or before the deadline date at the Division of Research Grants, NIH, or
 2. Sent by first class mail, postmarked on or before the deadline date, and received by the granting agency in time for submission to the independent review group. (Applicants are cautioned to request a legible U.S. Postal Service postmark or to use express mail or certified mail and to obtain a legible dated mailing receipt from the U.S. Postal Service. Private metered postmarks will not be acceptable as proof of timely mailing.)
- B. Applications submitted by other means. Applications submitted by any means except mailing first class through the U.S. Postal Service will be considered as meeting the deadline only if they are physically received at a place specified above before close of business on or before the deadline date.
- C. Late applications. Applications which do not meet the criteria in either paragraph 1. or 2. are considered late applications. In that event, an

application will not be considered in the current competition and will be returned to the applicant.

It is anticipated that awards will be made as early as May 1, 1983.

VIII. FOR FURTHER INFORMATION CONTACT:

Jack E. McCracken, Ph.D.
Acting Chief, Grants Administration and
Review Branch
Parklawn Building - Room 8-63
5600 Fishers Lane
Rockville, Maryland 20857

Telephone: (301) 443-4496

or

Mr. Joseph West
Grants Management Officer, NIOSH
Parklawn Building - Room 8-23
5600 Fishers Lane
Rockville, Maryland 20857

Telephone: (301) 443-3122

ANNOUNCEMENT

AVAILABILITY OF REQUESTS FOR APPLICATIONS (RFA)

DIVISION OF HEART AND VASCULAR DISEASES
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

CORONARY ARTERY REACTIVITY, INJURY AND THROMBOSIS

Application Receipt Date: April 15, 1983

The Cardiac Diseases Branch, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute (NHLBI) expects to publish a Request for Applications (RFA) on the above subject, on or about December 31, 1982. Copies of this RFA are currently available from staff of the NHLBI.

This program will support basic research on coronary artery spasm and coronary thrombosis as contributing factors to myocardial infarction and rest angina. Projects should be focused on the biology and pathophysiology of coronary arteries in the context of spasm and thrombosis. Also of interest are the effects which spasm may have in contributing to the formation of an occlusive thrombus and conversely the effects the metabolic products of a thrombus may have in inducing spasm. This announcement may be of particular interest to investigators with expertise in coronary physiology, rheology, hematology, coagulation, biochemistry, pathology, immunology, pharmacology and electrophysiology.

Request for copies of the RFA should be addressed to:

Constance Weinstein, Ph.D.
Deputy Chief, Cardiac Diseases Branch
National Heart, Lung, and Blood Institute
Federal Building - Room 312
7550 Wisconsin Avenue
Bethesda, Maryland 20205

Telephone: (301) 496-1081

DYSRHYTHMIAS IN THE DEVELOPING AND IMMATURE HEART

Application Receipt Date: April 15, 1983

The Cardiac Diseases Branch, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute (NHLBI) expects to publish a Request for Applications (RFA) on the above subject on or about December 31, 1982. Copies of this RFA are currently available from staff of the NHLBI.

This program will support research on basic developmental electrophysiology and on control of dysrhythmias in the young. Fundamental studies of how development influences impulse generation, conduction and mechanisms of reentry are appropriate. Also of interest are studies which elucidate the differences between immature and adult cardiac tissues in their responses to pharmacologic interventions. Projects may involve studies on cells, animal models and/or patients. However, clinical trials on clinical drug validation studies would not be responsive to the request. This announcement may be of particular interest to investigators with expertise in embryology, physiology, pharmacology, biophysics and electrophysiology.

Request for copies of the RFA should be addressed to:

Zena McCallum
Cardiac Diseases Branch
National Heart, Lung, and Blood Institute
Federal Building - Room 3C-06
7550 Wisconsin Avenue
Bethesda, Maryland 20205

Telephone: (301) 496-1081

BIOBEHAVIORAL FACTORS AFFECTING HYPERTENSION IN BLACKS

Application Receipt Date: April 15, 1983

The Behavioral Medicine Branch, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute (NHLBI) expects to publish a Request for Applications (RFA) on or about December 31, 1982. Copies of this RFA are currently available from staff of the NHLBI.

This program will support research to gain basic information of possible blood pressure and other physiological differences between Black and White populations in response to specific behavioral/psychological stressors. The proposed research must address the interaction of selected behavioral and physiological variables relevant to the development of hypertension among population subgroups. This announcement may be of particular interest to investigators with interdisciplinary expertise in studies of cardiovascular responses to controlled psychological stimuli.

Request for copies of the RFA should be addressed to:

Dr. Katrina W. Johnson
National Heart, Lung, and Blood Institute
Federal Building - Room 604
7550 Wisconsin Avenue
Bethesda, Maryland 20205

Telephone: (301) 496-9380

CARDIAC HYPERTROPHY AND FAILURE IN CHRONIC HYPERTENSION

Application Receipt Date: April 15, 1983

The Hypertension and Kidney Diseases Branch, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute (NHLBI) expects to publish a Request for Applications (RFA) on the above subject on or about December 31, 1982. Copies of this RFA are currently available from staff of the NHLBI.

This program will support a broad range of new research projects seeking to characterize the transition from normal cardiac structure and function to cardiac hypertrophy and cardiac failure in experimental models with chronic hypertension. The range includes the attendant hemodynamic, morphological, histological, physiological, and biochemical changes affecting stromal, muscular, and vascular components of the heart, as well as identification of points in the process where changes are "reversible" and where they are "irreversible."

Letters of intent are encouraged to be submitted by February 15, 1983. Request for copies of the RFA should be addressed to:

Dr. John B. Dunbar
National Heart, Lung, and Blood Institute
Federal Building - Room 4C08
7550 Wisconsin Avenue
Bethesda, Maryland 20205

Telephone: (301) 496-1857

ANNOUNCEMENT

PREVENTIVE CARDIOLOGY ACADEMIC AWARD

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

Application Receipt Date: April 1, 1983

I. BACKGROUND

- A. The Division of Heart and Vascular Diseases of the National Heart, Lung, and Blood Institute (NHLBI), has initiated the Preventive Cardiology Academic Award to provide a stimulus for the development of a preventive cardiology curriculum in those schools of medicine and osteopathy that do not have one and to strengthen and improve the preventive cardiology curriculum in those schools that do. Each school of medicine or osteopathy in the United States and its possessions or territories is eligible to compete for one award for a project period that does not exceed five years. The number of awards made each year will depend upon the merit of the applications received and availability of funds.

II. PURPOSE

- A. For the purposes of the Preventive Cardiology Academic Award, the term preventive cardiology is used to define the area of cardiovascular medicine having a special concern with the development of knowledge and the application of knowledge directed at the prevention of heart and vascular diseases. This includes the area of primary prevention of cardiovascular diseases in infants, children, and adults who are at risk of developing such diseases and the reduction of preventable complications or disability in persons who have already developed cardiovascular disease.
- B. This award is intended to:
 1. Encourage the development of a high quality preventive cardiology curriculum in schools of medicine and osteopathy that will significantly increase the opportunities for students and house staff to learn both the principles and practice of preventive cardiology.
 2. Develop promising faculty whose interest and training are in preventive cardiology teaching, research, and practice.

This program is described in the Catalog of Federal Domestic Assistance No. 13.837, Heart and Vascular Diseases Research. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410 as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to A-95 Clearinghouse or Health Systems Agency review.

3. Develop established faculty who have a major commitment to and possess educational skills for teaching preventive cardiology.
4. Facilitate interchange of educational ideas and methods applicable to teaching preventive cardiology among awardees and institutions.
5. Develop at the grantee institution the ability to strengthen continuously the improved preventive cardiology curriculum, with local funds, subsequent to the award.

III. CRITERIA FOR THE AWARD

Competitive review of proposals will include an evaluation of the evidence of commitment of both the sponsoring institution and the head of the cardiology division to the accomplishment of the objectives of the award as well as the qualifications, interest and commitment of the candidate to undertake responsibility for implementing a high quality preventive cardiology curriculum. Sponsorship of the candidate must be by the head of the division responsible for the teaching and practice of cardiology in the institution. Joint appointments with other departments or schools such as Preventive Medicine, Pediatrics or Epidemiology are encouraged when they would lead to a meaningful enhancement of the curriculum, extend concepts of prevention to other teaching areas or enhance the candidate's professional development in preventive cardiology teaching, research or practice. Multidisciplinary programs are encouraged.

The candidate must have sufficient clinical training and research experience in cardiology to be able to develop and implement a high quality curriculum within the institution. If the candidate's background requires further educational development, the plans to acquire this additional training should be described. Relevant training in epidemiology, clinical trials, behavioral science or other areas could be advantageous in the broader role of the candidate in stimulating preventive cardiology concepts among other health professionals in the institution.

IV. PROVISIONS OF THE AWARD

The non-renewable Preventive Cardiology Academic Award will include funds for the awardee's salary, fringe benefits, funds for curriculum development, and actual indirect costs not to exceed 8% of total allowable direct costs.

The applicant may request salary support up to \$30,000 per year. In addition to this amount, fringe benefits may be requested at the applicable institutional rate.

The applicant must devote a minimum of 50% time to this grant and the salary which is requested may not exceed the time or effort to be devoted to the Preventive Cardiology Academic Award. The total salary on which it is based must be consistent both with the established salary structure at the institution and with salaries actually provided by the institution from its own funds to other staff members of equivalent qualifications, rank, and responsibilities in the department concerned. If full-time salaries are not currently paid to comparable staff members, the proposed salary must be appropriately related to the existing part-time salary structure. The awardee may devote up to 50% effort as principal or participating investigator on an NIH-supported grant(s) or contract(s) and may be remunerated from the grant(s) or contract(s) accordingly.

ANNOUNCEMENT

DEVELOPMENT OF MYELOMA OR HUMAN B CELL LINES SUITABLE FOR SOMATIC CELL HYBRIDIZATION TO PRODUCE HUMAN MONOCLONAL ANTIBODIES NATIONAL CANCER INSTITUTE

Application Receipt Dates: March 1, July 1, November 1

The National Cancer Institute (NCI) invites applications for support of research related to establishing human myeloma or B cell lines appropriate for use in monoclonal antibody production.

The fusion of mouse myeloma cells in continuous culture with immunized mouse spleen cells to produce hybrid cells each producing a single monospecific antibody was accomplished by Kohler and Milstein in 1975 and has revolutionized immunology. The fact that these hybrids are capable of being propagated indefinitely in tissue culture or as a transplantable tumor in histocompatible mice, has made possible the production of unlimited amounts of monoclonal antibodies with selected specificity.

There has been great interest in applying these monoclonal antibodies to the clinical problems of cancer management for immunodiagnosis, immunolocalization and immunotherapy. For in vivo use in human patients with or suspected of having cancer there are obvious advantages in utilizing human monoclonal antibody rather than one of mouse or rat origin.

The human myeloma and B cell lines that are currently available for fusion with human immune B lymphocytes have not shown the efficiency in fusion, cloning and antibody synthesis that is obtainable with the available mouse myeloma lines. For this reason, the NCI is interested in stimulating the development of human cell lines of plasma cell or B lymphocyte origin that are capable of serving as fusion partners for the production of human-human hybridomas synthesizing human monoclonal antibody. Special attention should be given to cell lines that are non-secretors of immunoglobulin and are not contaminated by viral infection.

Investigators able to conduct the above studies are encouraged to submit a grant application to the Division of Research Grants (DRG).

This program is described in the Catalog of Federal Domestic Assistance No. 13.396, Cancer Biology. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to A-95 Clearinghouse or Health Systems Agency review.

METHOD OF APPLYING

Applications should be submitted on form PHS-398 (Rev. 5/80), which is available in the grants and contracts business office at most academic and research institutions or from the Division of Research Grants, National Institutes of Health (NIH). Review and award of the successful applications will be through the usual NIH procedures governing research project grants.

The phrase "PREPARED IN RESPONSE TO PROGRAM ANNOUNCEMENT: DEVELOPMENT OF MYELOMA OR HUMAN B CELL LINES SUITABLE FOR SOMATIC CELL HYBRIDIZATION TO PRODUCE HUMAN MONOCLONAL ANTIBODIES" should be typed under item 2 on page one of the application.

In addition, a brief covering letter should accompany the application indicating it is being submitted in response to this program announcement. The original and six copies of the application should be sent or delivered to:

Applications Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building - Room 240
Bethesda, Maryland 20205

For further information, investigators are encouraged to contact:

K. Robert McIntire, M.D.
Chief, Diagnosis Branch
Program Director, Diagnosis Program
Division of Cancer Biology and Diagnosis
National Cancer Institute
Building 31 - Room 3A10
Bethesda, Maryland 20205

Telephone: (301) 496-1591

In order to alert the Diagnosis Program to the submission of applications in response to this announcement, a copy of the covering letter should be sent to Dr. McIntire.

ANNOUNCEMENT

RESEARCH GRANTS ON HORMONES AND EPILEPSY

NATIONAL INSTITUTE OF NEUROLOGICAL AND COMMUNICATIVE DISORDERS AND STROKE

Application Receipt Dates: March 1, July 1, November 1

I. INTRODUCTION

The Epilepsy Branch, Neurological Disorders Program of the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) encourages the submission of research grant applications (R01) on the role of hormones in epilepsy.

II. BACKGROUND

Even though there is a large and ever increasing amount of information on endocrine-brain relationships, the role of hormones in epilepsy is not well defined. It is becoming obvious that hormones can significantly alter brain activity either through excitatory or inhibitory mechanisms. Conversely, there is a growing body of evidence that indicates seizures and antiepileptic drugs can influence hormonal balance.

A number of hormones influence maturation of mammalian brain. Thyroid insufficiency during early development may result in increased brain excitability secondary to delays in maturation of inhibitory neuronal activity. A variety of adverse conditions may lead to changes in endocrine function with delays in brain development, which may lead to epilepsy. In the adult brain, hormones may influence epilepsy by altering excitability of cortical or limbic regions. Ovarian hormones and thyroid hormones appear to have direct effects on CNS excitability. Thyroid hormones influence the synthesis of neurotransmitters and alter receptor sensitivity. Glucocorticoids enhance the activity of enzymes in the synthesis of monoamines.

Seizures and antiepileptic drugs can have significant influences on hormonal balance. Phenytoin has been shown to increase the rate of release of glucocorticoids and antagonizes the effects of parathyroid hormone on calcium metabolism. Mean levels of a number of hormones including prolactin, cortisol and cholesterol have been shown to be elevated in epileptic patients, possibly due to an alteration in neurotransmitter activity during the seizure.

This program is described in the Catalog of Federal Domestic Assistance No. 13.854, Fundamental Neurosciences. Grants will be awarded under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grants policies and Federal Regulations 42 CFR Part 52 and 45 Part 74. This program is not subject to A-95 Clearinghouse or Health Systems Agency review.

Studies done to date indicate a relationship between hormones and epilepsy. Further research is needed to determine the basic physiological processes by which hormones influence seizure generation and spread, and how hormonal state can influence brain development and seizure susceptibility.

III. RESEARCH GOALS

Research grant applications should focus on the basic neurophysiology and endocrinology involved in the proconvulsant or anticonvulsant activity of hormones, as well as the effects of seizure activity on hormonal states. Related research supporting this effort would be appropriate. The primary research goals are: 1) to determine the influence of various hormones on brain development and generation of epileptiform discharges; 2) to determine the underlying physiological processes whereby hormones influence seizure generation and spread; and 3) to determine the influence of seizures and antiepileptic drugs on hormonal states.

IV. MECHANISM OF SUPPORT

Support for this program will be through the regular research project grant. Each successful applicant will plan, direct, and carry out the individual research project.

V. APPLICATION AND REVIEW PROCEDURES

Applications should be prepared on form PHS 398 (Rev. 5/80) following instructions contained in the application kit. Application kits are available from most institutional business offices, or may be obtained from the Division of Research Grants, at the address given below.

Applications must be responsive to the program announcement and the goals of NINCDS. They will be judged on scientific merit and program relevance in accordance with NIH policy and procedures involving peer review. An initial review will be made by the appropriate study section of the Division of Research Grants. A second level review will be made by the National Advisory Neurological and Communicative Disorders and Stroke Council.

Application receipt dates are: March 1, July 1 and November 1.

The phrase "NINCDS Program Announcement on Hormones and Epilepsy" should be typed in space No. 2 of the face page of the application. The original and six copies of the application should be mailed to:

Division of Research Grants
National Institutes of Health
Westwood Building - Room 240
5333 Westbard Avenue
Bethesda, Maryland 20205

One copy of the application is to be sent to the addressee below. Also, for further information applicants may contact:

William H. Pitlick, Ph.D.
Health Scientist Administrator
Epilepsy Branch
Neurological Disorders Program
National Institute of Neurological and
Communicative Disorders and Stroke
Federal Building - Room 118
7550 Wisconsin Avenue
Bethesda, Maryland 20205

Telephone: (301) 496-1917